This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Waardenburg syndrome, WS type I–IV바르덴브르그증후군 (백색증을 동반한)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.3 (albinism — Waardenburg syndrome with albinism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsWaardenburg syndrome, Waardenburg-Shah syndrome (WS4), auditory-pigmentary syndrome, Klein-Waardenburg syndrome (WS3)
C. Adult onsetPossibility of first manifestation in adulthood: low — Congenital sensorineural hearing loss, heterochromia iridis, and a white forelock are evident at birth or in early infancy and are diagnosed in childhood; first diagnosis in adulthood rarely occurs with mild pigmentary abnormalities or during family screening.
1. History1951 first description by the Dutch ophthalmologist Waardenburg → 1971 description of the Shah-Waardenburg type (WS4) → 1992 identification of the PAX3 gene → 4 subtypes and 6 causative genes elucidated.
2. CausesMutations of PAX3 (WS1/3), MITF (WS2), SOX10 (WS2/4), EDN3 (WS4), EDNRB (WS4), SNAI2 (WS2) → impaired differentiation and migration of neural crest cells → defective development of melanocytes and inner ear cells.
3. GeneticsWS1, 2, 3: mainly autosomal dominant (PAX3, MITF, SOX10, SNAI2). WS4: autosomal recessive (EDN3, EDNRB) or autosomal dominant (SOX10). Heritability of WS1 and 3 ~100%.
4. General epidemiologyAbout 2-3% of causes of congenital hearing loss. Worldwide prevalence about 1 in 42,000. Korea: not uncommon among children with congenital hearing loss. No large differences in prevalence between ethnic groups.
5. PathophysiologyDefects in differentiation, migration, and survival of neural crest cell (NCC)-derived melanocytes → loss of melanocytes in the stria vascularis of the inner ear → collapse of inner ear fluid ion homeostasis → sensorineural hearing loss; decreased pigmentation of skin, hair, and iris.
6. SymptomsCongenital sensorineural hearing loss (unilateral/bilateral), heterochromia iridis or iris hypopigmentation, white forelock (frontal white hair), dystopia canthorum (WS1, 3), depressed nasal root, arm abnormalities in WS3, Hirschsprung disease in WS4.
7. SignsIncreased inner canthal distance (W-index > 1.95, WS1), abnormal hearing tests (ABR, PTA), heterochromia iridis, hypopigmented skin patches, frontal white hair. WS4: signs of congenital megacolon (abdominal distension, constipation).
8. ScreeningWhen newborn hearing screening (AABR/OAE) fails and pigmentary abnormalities are found, differentiation of WS is performed. For those with a family history: molecular genetic testing is recommended proactively. The Korean newborn hearing screening program is utilized.
9. DiagnosisClinical criteria (Waardenburg Consortium): W-index, scoring of major/minor criteria. ABR/PTA hearing tests. NGS gene panel (PAX3, MITF, SOX10, EDNRB, EDN3, SNAI2). WS4: colonic imaging and rectal biopsy.
10. TreatmentNo curative treatment. Hearing loss: hearing aids or cochlear implantation (early intervention is decisive for language development). Pigmentary abnormalities: cosmetic management. WS4 Hirschsprung disease: surgery. Genetic counseling is essential.
11. PrognosisLanguage development and educational outcomes vary with the degree of hearing loss. Near-normal language development is possible with early hearing aids or cochlear implantation. Long-term prognosis is good after correction of WS4 Hirschsprung disease. Life expectancy is normal.
12. PreventionGenetic counseling, preimplantation genetic testing (PGT-M), prenatal molecular genetic diagnosis. Early hearing testing of affected children and optimization of the timing of cochlear implantation. Skin protection and regular ophthalmologic examination.
13. ReferencesWaardenburg PJ. A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root. Am J Hum Genet. 1951;3:195-253 … and 9 other papers

1. History

Waardenburg syndrome (WS) is an auditory-pigmentary syndrome systematically described in 1951 by the Dutch ophthalmologist and geneticist Petrus Johannes Waardenburg (1886-1979). During ophthalmic practice, Waardenburg observed families in which congenital hearing loss was accompanied by distinctive facial pigmentary abnormalities (heterochromia iridis, white forelock, dystopia canthorum), and published this new syndrome in 1951 in the American Journal of Human Genetics. In his early paper he had already described the autosomal dominant inheritance pattern of this disease and considerable variable expressivity.

Similar cases had been reported sporadically even before Waardenburg. In 1916, Jan van der Hoeve reported a case with congenital hearing loss and heterochromia iridis, and in the 1920s David Klein described a variant with arm malformations (hypoplasia of upper limb muscles, flexion contractures), which was later classified as WS type 3 (Klein-Waardenburg syndrome).

In 1971, Nitin Shah and Waardenburg described a subtype in which Hirschsprung disease (congenital megacolon) accompanies congenital hearing loss and pigmentary abnormalities, and it was named WS type 4 (Waardenburg-Shah syndrome). WS4 provided the conceptual basis that a migration defect of enteric neural crest cells causes loss of ganglion cells in the bowel.

In molecular genetics, in 1992 Tassabehji et al. first identified mutations of the PAX3 gene (paired box gene 3) as the cause of WS1 and WS3. In 1994, the MITF (microphthalmia-associated transcription factor) gene was identified as the cause of WS2, in 1998 SOX10, and subsequently the EDN3, EDNRB, and SNAI2 genes were identified in turn as causes of WS2 and WS4. In 2022, Lee et al. reported 9 novel variants of these genes in Korean WS patients by next-generation sequencing, contributing to molecular genetic research in Asian populations.

WS is now recognized as a complex syndrome with both clinical heterogeneity and genetic heterogeneity, and it is well known that even within a family with the same PAX3 mutation, the degree of hearing loss, the extent of pigmentary abnormalities, and the presence of dystopia canthorum can differ greatly. In Korea, early detection of WS-related congenital hearing loss and cochlear implantation are carried out through the newborn hearing screening program (introduced nationwide in 2007).


2. Causes

Waardenburg syndrome is caused by pathogenic mutations of genes encoding transcription factors and signaling molecules involved in the differentiation, migration, and survival of neural crest cells (NCC). The 6 major causative genes identified to date are classified by WS subtype as follows.

PAX3 gene (2q36.1): A transcription factor containing a paired box domain and a key factor regulating the differentiation and migration of neural crest cells. Heterozygous PAX3 mutations cause WS1 and WS3, and the mutation spectrum includes point mutations, deletions, and splicing variants. It is inherited as autosomal dominant, and homozygous mutations are associated with embryonic lethality or severe neural tube defects.

MITF gene (3p14.1-p12.3): Microphthalmia-associated transcription factor, an essential factor regulating melanocyte differentiation and survival and a downstream target of PAX3. Heterozygous MITF mutations cause WS2A and are also associated with the development of melanoma. SOX10 gene (22q13.1): An SRY-box transcription factor broadly involved in differentiation of the neural crest cell lineage and essential for peripheral nerve myelination (Schwann cells), enteric neural crest cells (enteric NCC), and melanocytes. SOX10 mutations cause WS2E (with inner ear structural abnormalities) and WS4C (with Hirschsprung disease), and patients with SOX10 mutations may have peripheral neuropathy or central nervous system myelin abnormalities (PCWH syndrome: peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, Hirschsprung disease).

EDN3 gene (20q13.32) and EDNRB gene (13q22.3): These encode endothelin-3 and its receptor (endothelin receptor type B), respectively, and this signaling pathway is essential for migration and survival of enteric neural crest cells and for melanocyte differentiation. Heterozygous mutations cause WS4A (EDNRB) and WS4B (EDN3) and are inherited as autosomal recessive or incomplete dominant. SNAI2 gene (8q11.21): Encodes Slug, a transcription factor regulating epithelial-mesenchymal transition (EMT), and homozygous SNAI2 mutations cause WS2D.

Summarizing genotype and subtype classification in a table: WS1 (PAX3, AD) — dystopia canthorum + auditory-pigmentary abnormalities; WS2 (MITF, SOX10, SNAI2, etc., AD/AR) — no dystopia canthorum + auditory-pigmentary abnormalities; WS3 (PAX3 homozygous or large deletion, AD/AR) — WS1 + arm abnormalities; WS4 (SOX10, EDN3, EDNRB, AD/AR) — WS2 + Hirschsprung disease. In about 10-15% of clinical WS patients, no pathogenic variant is found in the 6 known genes, so the existence of additional causative genes is expected.


3. Genetics

The mode of inheritance of Waardenburg syndrome differs by subtype. WS1 and WS3 are inherited as autosomal dominant (AD) due to heterozygous mutations of the PAX3 gene, with penetrance of about 100% but widely varying expressivity. Even within the same family, it is typical for some members to show only pigmentary abnormalities without hearing loss and others to have severe bilateral hearing loss. WS3 is also caused by more severe mutations (large deletions, homozygous variants) of the same gene as WS1.

WS2 is the most genetically heterogeneous subtype, mainly AD inheritance due to heterozygous mutations of MITF (WS2A), SNAI2 (WS2D), SOX10 (WS2E), etc., although an AR form due to homozygous SNAI2 mutations has also been reported. WS4 is mainly autosomal recessive (AR) inheritance due to homozygous or compound heterozygous mutations of EDNRB (WS4A) and EDN3 (WS4B), whereas heterozygous SOX10 mutations (WS4C) show AD or incomplete penetrance forms.

In terms of mutation spectrum, various types have been reported in PAX3, including missense, nonsense, frameshift, splicing, and large deletions. In MITF, missense variants of the basic helix-loop-helix domain are common. For SOX10 mutations, variants in the HMG box (DNA-binding domain) region are particularly associated with a severe phenotype. In Korean WS patients, a 2022 study by Lee et al. reported 9 novel variants in PAX3, SOX10, EDNRB, and MITF by NGS, showing variant diversity in East Asian populations. Currently, the ClinVar database lists hundreds of pathogenic variants and variants of uncertain significance (VUS) in WS-related genes.


4. General epidemiology

Waardenburg syndrome is a relatively not uncommon cause of syndromic hearing loss and is known to account for about 2-3% of causes of congenital sensorineural hearing loss worldwide. The worldwide prevalence is estimated at about 1 in 42,000, which is relatively common among syndromic genetic diseases accompanied by hearing loss. By subtype, WS1 accounts for about 20-40% of all WS, and WS2 is the most common at about 40-50% but has a low molecular confirmation rate because of large genetic heterogeneity. WS3 and WS4 are rare forms, each 5% or less.

The sex distribution is equal between men and women, according to the AD mode of inheritance. It occurs in all ethnic groups worldwide, and a bias toward a specific ethnic group or region is less evident than for HPS. However, there is an observation that WS4 with Hirschsprung disease is reported relatively more often in some parts of Africa.

In Korea, through the newborn hearing screening program implemented nationwide since 2007, congenital hearing loss is detected early, and a system for differentiating syndromic hearing loss including WS has been established. According to guidelines of the Korean Otological Society and related societies, differentiation of syndromic hearing loss, including a WS gene panel test, is recommended when newborn hearing screening fails and pigmentary abnormalities are present. In the rare disease statistics of the Health Insurance Review & Assessment Service, WS is listed as a disease eligible for Special Copayment Reduction V117, and new registrations are estimated at several dozen to several hundred each year.


5. Pathophysiology

The core pathogenesis of Waardenburg syndrome is a developmental disorder of neural crest cells (NCC). Neural crest cells originate from the dorsal region of the neural tube at about 4 weeks of development and migrate throughout the body, differentiating into various cells such as melanocytes (pigment cells), peripheral nerve Schwann cells, craniofacial cartilage and skeleton, and ganglion cells of the enteric nervous system.

The causative genes of WS (PAX3, MITF, SOX10, EDNRB/EDN3, SNAI2) are key components of the NCC transcription factor network and signaling pathways, and when a heterozygous mutation occurs in any one of them, differentiation, migration, and survival of melanocyte-lineage NCC are impaired. Specifically, PAX3 is required for epithelial-mesenchymal transition (EMT) of NCC and MITF transcriptional activation, and MITF, as the master regulator of melanocyte differentiation, promotes expression of melanin synthesis enzyme genes such as TYRP1, DCT, and MC1R. SOX10 cooperates with MITF to induce melanocyte differentiation and is also required for differentiation of enteric NCC into ganglion cells and for Schwann cell myelination. The EDNRB/EDN3 signaling pathway is decisive in enabling enteric NCC to migrate and colonize the entire bowel sufficiently.

In particular, the pathogenesis in the inner ear is clinically important. Melanocytes forming the basal cell layer of the stria vascularis of the inner ear are essential for maintaining the high-potassium environment of the endolymph. Because these melanocytes originate from NCC, when inner ear melanocytes are absent owing to mutations of WS causative genes, a cascade occurs: stria vascularis dysfunction → decreased endolymph potassium concentration → loss of hair cell resting potential (endocochlear potential) → sensorineural hearing loss. This mechanism explains why hearing loss occurs in WS even though the inner ear structure itself (organ of Corti) is normal.

Failure of enteric NCC migration (SOX10, EDNRB/EDN3 defects) causes loss of ganglion cells of Auerbach's plexus and Meissner's plexus in the distal bowel, leading to Hirschsprung disease (WS4). Therefore, WS4 is a composite phenotype reflecting developmental disorders of both independent NCC lineages (the melanocyte lineage + the enteric neural crest cell lineage).


6. Symptoms

The clinical symptoms of Waardenburg syndrome differ somewhat by subtype, but the core symptoms common to all subtypes are congenital sensorineural hearing loss and pigmentary abnormalities.

Auditory symptoms: Congenital sensorineural hearing loss occurs in about 20-57% of WS patients. It can be unilateral or bilateral, and moderate to profound or greater hearing loss is characteristic. The hearing loss is non-progressive and in most cases is fixed from birth, although worsening over time has rarely been reported in some. The prevalence of hearing loss is higher in WS2 and WS4 than in WS1 (~57% vs ~20-25%).

Pigmentary abnormalities: Heterochromia iridis (different iris color in the two eyes) or hypopigmented iris (characteristic bright blue iris), white forelock, and depigmented skin macules appear. These pigmentary abnormalities are incompletely penetrant, so various pigmentary phenotypes are observed even within families with the same genotype. A white forelock is the most characteristic appearance finding in WS and may spontaneously revert to normally pigmented hair after childhood.

Facial abnormalities: Dystopia canthorum appears characteristically in WS1 and WS3. This is a finding in which the inner canthal distance is increased so that the eyes appear far apart (broad nasal root), and because the actual interpupillary distance is normal, it is distinguished from true hypertelorism. In WS3, upper limb abnormalities (upper limb muscle hypoplasia, flexion contractures, brachydactyly) additionally accompany. In WS4, Hirschsprung disease (congenital megacolon) appears in addition to the symptoms of WS2, causing symptoms such as neonatal constipation, abdominal distension, and intestinal obstruction. In WS4C due to SOX10 mutations, neurological symptoms (peripheral neuropathy, leukoencephalopathy) may accompany.


7. Signs

Characteristic signs of Waardenburg syndrome are identified on physical examination and testing. Facial measurement: The W-index proposed by Arias (1971) is used for diagnosing WS1. W-index = X + Y + a/b (X: inner canthal distance/face width, Y: interpupillary-nasal root distance/face width, a/b: inner canthal distance/interpupillary distance); a W-index >1.95 is judged positive for dystopia canthorum. WS1 and WS3 meet this criterion. A broad, high nasal root and synophrys (unibrow) are also observed.

Hearing tests: In newborns, hearing screening using automated auditory brainstem response (AABR) or otoacoustic emissions (OAE) is used, followed by evaluation of the degree of hearing loss by auditory brainstem response (ABR), and in adults pure-tone audiometry (PTA). Mainly a high-frequency hearing loss pattern (cochlear type) is seen, although involvement of all frequencies is also possible. Inner ear structural abnormalities on temporal bone CT/MRI have been reported in some WS2 (SOX10 mutations).

Pigmentary findings: Slit-lamp examination shows heterochromia or hypopigmentation of the iris. Hypopigmented lesions of the skin and hair are observed, and hypopigmented macules become distinct on Wood's lamp examination. Signs of WS4: typical findings of Hirschsprung disease such as distal colonic narrowing on abdominal X-ray or barium enema and loss of ganglion cells on rectal biopsy. In SOX10 mutations (WS4C), abnormal nerve conduction studies and white matter signal abnormalities on brain MRI may be found.


8. Screening

Waardenburg syndrome is not currently included in the general newborn screening panel, but can be screened indirectly through newborn hearing screening (AABR/OAE). In Korea, hearing screening has been performed on all newborns nationwide since 2007, and WS should be suspected immediately when a newborn who fails the test also has pigmentary abnormalities (heterochromia iridis, white forelock, skin depigmentation).

Criteria for suspecting WS: Congenital sensorineural hearing loss + one or more of the following: ① heterochromia iridis or iris hypopigmentation, ② white forelock, ③ hypopigmented skin patches, ④ dystopia canthorum (W-index >1.95), ⑤ family history (autosomal dominant pattern). WS is clinically diagnosed by the Waardenburg Consortium criteria if two or more major criteria, or one major criterion plus two or more minor criteria, are met. When there is a family history, confirmation of carrier/affected status by molecular genetic testing is recommended regardless of symptoms.

When WS4 is suspected (with Hirschsprung disease), early neonatal abdominal imaging, suction rectal biopsy, and SOX10, EDN3, EDNRB gene panel testing are performed proactively. WS4 should also be included in the differential diagnosis when bowel dilatation is found on prenatal ultrasound.


9. Diagnosis

Diagnosis of Waardenburg syndrome is established by clinical criteria together with molecular genetic testing. According to the Waardenburg Consortium clinical criteria (1992), the major criteria are: (1) congenital sensorineural hearing loss, (2) iris pigmentary abnormalities (heterochromia iridis, hypopigmented iris, pigment patches in the iris), (3) hair pigmentary abnormalities (white forelock, premature graying, whitening of eyelashes/eyebrows), (4) dystopia canthorum (W-index >1.95), (5) family history of WS in a first-degree relative. The minor criteria are: (1) hypopigmented skin patches, (2) synophrys, (3) broad, high nasal root, (4) hypoplastic alae nasi, (5) premature graying (before age 30). WS is clinically diagnosed when two major criteria, or one major criterion plus two minor criteria, are met. To distinguish WS1/WS3, the presence of dystopia canthorum is used, and to distinguish WS2/WS4, the presence of accompanying Hirschsprung disease is used.

Molecular genetic diagnosis: The NGS-based WS gene panel (PAX3, MITF, SOX10, EDNRB, EDN3, SNAI2) is currently the standard confirmatory method. When a mutation is detected, subtype classification and accurate genetic counseling become possible. For PAX3, MITF, and SOX10, testing for large deletions and rearrangements (MLPA, array CGH) is sometimes needed. Hearing evaluation: ABR (auditory brainstem response), PTA (pure-tone audiometry), temporal bone CT/MRI. Gastrointestinal evaluation for WS4: abdominal X-ray, barium enema, anorectal manometry, suction rectal biopsy (confirmation of aganglionosis). In patients with SOX10 mutations, brain MRI and nerve conduction studies are recommended to evaluate for accompanying PCWH syndrome.


10. Treatment

There is currently no curative treatment (treatment at the gene level) for Waardenburg syndrome, and symptom-based treatment and rehabilitation for each clinical manifestation are the core.

Treatment of hearing loss: Early auditory intervention is decisively important for language development. Hearing aids are used in mild to moderate hearing loss, and cochlear implantation is the first-line treatment in hearing loss of moderate or greater severity. It is reported that language development outcomes after cochlear implantation in WS patients are similar to or better than those in patients with nonsyndromic hearing loss. The earlier the implantation, the more favorable for language development, and in Korea implantation after 12 months of age, and where appropriate at 6-12 months, is considered. Before cochlear implantation, cochlear structural abnormalities should be evaluated by temporal bone CT, and the frequency of inner ear malformations is high in WS2 (SOX10 mutations).

Management of pigmentary abnormalities: Hypopigmented skin patches and a white forelock do not cause functional problems, but when treatment is desired for psychological or cosmetic reasons, hair dyeing and laser treatment (limited indication for skin patches) are considered. Sun protection is important for preventing skin cancer. Heterochromia iridis is not a target of treatment and in most cases does not affect vision.

Treatment of Hirschsprung disease in WS4: After colostomy in the neonatal period, definitive surgery (Swenson, Soave, Duhamel pull-through operations) is performed after growth. On long-term follow-up, bowel function gradually improves. SOX10-related neurological complications: There is no specific treatment for peripheral neuropathy and leukoencephalopathy, but physical therapy, occupational therapy, and special education support are needed. Genetic counseling and psychological support services should be provided to all WS patients and families. Preventive options before and during pregnancy through preimplantation genetic diagnosis (PGT-M) and prenatal molecular genetic testing should be explained.


11. Prognosis

The life expectancy of patients with Waardenburg syndrome is close to normal in most subtypes. The degree of hearing loss and whether early intervention is made are the factors with the greatest impact on patients' quality of life and on language, education, and occupational outcomes. When language development is supported in a timely manner through early hearing aid use or cochlear implantation, WS patients can achieve near-normal language ability and academic achievement.

Pigmentary abnormalities (heterochromia iridis, white forelock, hypopigmented skin patches) are not medically dangerous, but social prejudice about appearance and psychological burden can affect quality of life, so psychological support is important. WS4 (with Hirschsprung disease) generally has a good long-term prognosis after appropriate surgical treatment, but residual defecation disorders (constipation, encopresis) and bowel complications may persist in some. PCWH syndrome due to SOX10 mutations adds neurological disability from demyelination of the central and peripheral nervous system, making the prognosis more complex, and neurological decline may be progressive, so careful follow-up is needed.

Overall, WS is a disease in which patients can lead productive and independent lives with appropriate hearing rehabilitation, genetic counseling, and multidisciplinary follow-up (otolaryngology, medical genetics, gastrointestinal surgery, ophthalmology, pediatrics).


12. Prevention

Primary prevention of Waardenburg syndrome is achieved through genetic counseling and reproductive options. Couples in whom WS has been diagnosed or who are identified as carriers should be clearly informed of the risk of disease in each pregnancy (50% for AD inheritance, 25% for AR inheritance), and offered the following options: (1) selection of affected embryos by preimplantation genetic testing (PGT-M) followed by transfer of unaffected embryos, (2) prenatal molecular genetic testing (fetal DNA analysis by chorionic villus sampling or amniocentesis), (3) natural conception followed by perinatal hearing screening and preparation for early intervention.

As secondary prevention in already affected children, the most important thing is to prevent delayed language development by diagnosing hearing loss early through newborn hearing screening and starting auditory intervention (hearing aids, cochlear implants) as early as possible. In children with WS4, neonatal signs of Hirschsprung disease (constipation, abdominal distension) are observed carefully to prevent intestinal obstruction complications through early diagnosis and surgical treatment. Applying sunscreen and wearing protective clothing on hypopigmented skin patches lowers the risk of skin cancer (melanoma, squamous cell carcinoma). An integrated management system is also established through regular ophthalmologic examination, hearing follow-up tests, and medical genetics follow-up counseling. Strengthening the self-management capacity of patients and families through WS patient support groups and educational materials also helps long-term prognosis.


13. References

  1. Waardenburg PJ. A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet. 1951;3(3):195-253. PMID: 14853950
  2. Tassabehji M, Newton VE, Read AP. Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet. 1994;8(3):251-255. doi:10.1038/ng1194-251
  3. Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat. 2010;31(4):391-406. doi:10.1002/humu.21211
  4. Lee HJ, Jung J, Shin JW, et al. Identification of nine novel variants across PAX3, SOX10, EDNRB, and MITF genes in Waardenburg syndrome with next-generation sequencing. Mol Genet Genomic Med. 2022;10(12):e2082. doi:10.1002/mgg3.2082
  5. Bondurand N, Pingault V, Goerich DE, et al. Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet. 2000;9(13):1907-1917. doi:10.1093/hmg/9.13.1907
  6. Amiel J, Sproat-Emison E, Garcia-Barcelo M, et al. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet. 2008;45(1):1-14. doi:10.1136/jmg.2007.053959
  7. Tamayo ML, Gelvez N, Rodriguez M, et al. Screening program for Waardenburg syndrome in Colombia: clinical definition and phenotypic variability. Am J Med Genet A. 2008;146A(8):1026-1031. doi:10.1002/ajmg.a.32232
  8. Kontorinis G, Lenarz T, Lesinski-Schiedat A, et al. Cochlear implantation in Waardenburg syndrome. Otol Neurotol. 2010;31(5):715-718. doi:10.1097/MAO.0b013e3181e0aa1f
  9. Arias S. Genetic heterogeneity in the Waardenburg syndrome. Birth Defects Orig Artic Ser. 1971;7(4):87-101. PMID: 5173626
  10. Read AP, Newton VE. Waardenburg syndrome. J Med Genet. 1997;34(8):656-665. doi:10.1136/jmg.34.8.656